Details for New Drug Application (NDA): 062178
✉ Email this page to a colleague
NDA 062178 describes GRISACTIN ULTRA, which is a drug marketed by Wyeth Ayerst and is included in two NDAs. Additional details are available on the GRISACTIN ULTRA profile page.
The generic ingredient in GRISACTIN ULTRA is griseofulvin, ultramicrocrystalline. There is one drug master file entry for this compound. Additional details are available on the griseofulvin, ultramicrocrystalline profile page.
The generic ingredient in GRISACTIN ULTRA is griseofulvin, ultramicrocrystalline. There is one drug master file entry for this compound. Additional details are available on the griseofulvin, ultramicrocrystalline profile page.
Summary for 062178
| Tradename: | GRISACTIN ULTRA |
| Applicant: | Wyeth Ayerst |
| Ingredient: | griseofulvin, ultramicrocrystalline |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 125MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
